{"transactions":[{"id":1008727,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-11-04T22:03:27.000Z","date":"2025-10-31","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One fourth of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 31, 2025."}],"balance_after":250000,"derivative":{"exercise_price":0.9877,"expiration_date":"2035-10-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001755495-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000175549525000003/primary_doc.xml","form_type":"4"}},{"id":1268097,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-14T22:17:32.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, February 12, 2025."}],"balance_after":50000,"derivative":{"exercise_price":1.59,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-25-014315","document":"tm256716-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925014315/tm256716-4_4seq1.xml","form_type":"4"}},{"id":1486924,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:05:08.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":2409928,"source":{"system":"sec-edgar","filing":"0000950170-24-070597","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024070597/ownership.xml","form_type":"4"}},{"id":1895165,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T21:00:51.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":2374928,"source":{"system":"sec-edgar","filing":"0001209191-23-029099","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123029099/doc4.xml","form_type":"4"}},{"id":1897162,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-11T22:10:29.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal annual installments on May 10, 2024, May 10, 2025, May 10, 2026 and May 10, 2027 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":1.42,"expiration_date":"2033-05-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-028846","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123028846/doc4.xml","form_type":"4"}},{"id":1984655,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer & COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-01T21:49:34.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":46487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":46487,"derivative":{"exercise_price":2.14,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":46487},"source":{"system":"sec-edgar","filing":"0001209191-23-014158","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123014158/doc4.xml","form_type":"4"}},{"id":2263865,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T20:23:59.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable upon the earlier to occur of (i) May 17, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":27500,"derivative":{"exercise_price":4.6,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0000899243-22-018820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322018820/doc4.xml","form_type":"4"}},{"id":2316978,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer & COO"}}],"security":"Common Stock","published_at":"2022-03-29T01:04:44.000Z","date":"2022-03-24","kind":"tax_withholding","acquired":false,"shares":33465,"price":0.4848,"value":16223.832,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs."}],"balance_after":2671845,"source":{"system":"sec-edgar","filing":"0001209191-22-021395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122021395/doc4.xml","form_type":"4"}},{"id":2316977,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer & COO"}}],"security":"Common Stock","published_at":"2022-03-29T01:04:44.000Z","date":"2022-03-24","kind":"grant","acquired":true,"shares":140823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award."}],"balance_after":2705310,"source":{"system":"sec-edgar","filing":"0001209191-22-021395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122021395/doc4.xml","form_type":"4"}},{"id":2383026,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer & COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T22:12:05.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":160000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-22-011787","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122011787/doc4.xml","form_type":"4"}},{"id":2693586,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-27T20:47:14.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":22500,"derivative":{"exercise_price":21.51,"expiration_date":"2031-05-24","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000899243-21-020862","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321020862/doc4.xml","form_type":"4"}},{"id":2779879,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2021-03-18T20:38:07.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":571428,"price":1.75,"value":999999.0,"ownership":{"direct":true},"balance_after":2564487,"source":{"system":"sec-edgar","filing":"0001209191-21-021773","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021773/doc4.xml","form_type":"4"}},{"id":2814245,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-04T01:36:52.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":7546,"price":38.6321,"value":291517.8266,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.50 to $38.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2339928,"source":{"system":"sec-edgar","filing":"0001209191-21-017536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017536/doc4.xml","form_type":"4"}},{"id":2814244,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-04T01:36:52.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":7142,"price":38.2181,"value":272953.6702,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.50 to $38.495. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2347474,"source":{"system":"sec-edgar","filing":"0001209191-21-017536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017536/doc4.xml","form_type":"4"}},{"id":2814243,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-04T01:36:52.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":1300,"price":37.0104,"value":48113.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.50 to $37.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2354616,"source":{"system":"sec-edgar","filing":"0001209191-21-017536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017536/doc4.xml","form_type":"4"}},{"id":2814242,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-04T01:36:52.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":1803,"price":39.1015,"value":70500.0045,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.84 to $39.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2355916,"source":{"system":"sec-edgar","filing":"0001209191-21-017536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017536/doc4.xml","form_type":"4"}},{"id":2814241,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-04T01:36:52.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":9001,"price":38.2966,"value":344707.6966,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.84 to $38.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2357719,"source":{"system":"sec-edgar","filing":"0001209191-21-017536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017536/doc4.xml","form_type":"4"}},{"id":2814240,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-04T01:36:52.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":4190,"price":37.2765,"value":156188.535,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.84 to $37.83. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2366720,"source":{"system":"sec-edgar","filing":"0001209191-21-017536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017536/doc4.xml","form_type":"4"}},{"id":2814239,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-04T01:36:52.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":700,"price":39.53,"value":27671.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.515 to $39.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2370910,"source":{"system":"sec-edgar","filing":"0001209191-21-017536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017536/doc4.xml","form_type":"4"}},{"id":2814238,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-04T01:36:52.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":20584,"price":38.7323,"value":797265.6632,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.49 to $39.478. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2371610,"source":{"system":"sec-edgar","filing":"0001209191-21-017536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017536/doc4.xml","form_type":"4"}},{"id":2814237,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-04T01:36:52.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":11570,"price":38.275,"value":442841.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.49 to $38.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2392194,"source":{"system":"sec-edgar","filing":"0001209191-21-017536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017536/doc4.xml","form_type":"4"}},{"id":2839639,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-24T00:44:40.000Z","date":"2021-02-23","kind":"sale","acquired":false,"shares":600,"price":40.9708,"value":24582.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.77 to $41.225. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2403764,"source":{"system":"sec-edgar","filing":"0001209191-21-013486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013486/doc4.xml","form_type":"4"}},{"id":2839638,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-24T00:44:40.000Z","date":"2021-02-23","kind":"sale","acquired":false,"shares":2300,"price":40.1278,"value":92293.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.76 to $40.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2404364,"source":{"system":"sec-edgar","filing":"0001209191-21-013486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013486/doc4.xml","form_type":"4"}},{"id":2839637,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-24T00:44:40.000Z","date":"2021-02-23","kind":"sale","acquired":false,"shares":4825,"price":39.1071,"value":188691.7575,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.75 to $39.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2406664,"source":{"system":"sec-edgar","filing":"0001209191-21-013486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013486/doc4.xml","form_type":"4"}},{"id":2839636,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-24T00:44:40.000Z","date":"2021-02-23","kind":"sale","acquired":false,"shares":1125,"price":38.3254,"value":43116.075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.74 to $38.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2411489,"source":{"system":"sec-edgar","filing":"0001209191-21-013486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013486/doc4.xml","form_type":"4"}},{"id":2839635,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-24T00:44:40.000Z","date":"2021-02-22","kind":"sale","acquired":false,"shares":380,"price":43.4021,"value":16492.798,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.34 to $43.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2412614,"source":{"system":"sec-edgar","filing":"0001209191-21-013486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013486/doc4.xml","form_type":"4"}},{"id":2839634,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-24T00:44:40.000Z","date":"2021-02-22","kind":"sale","acquired":false,"shares":11050,"price":42.797,"value":472906.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.31 to $43.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2412994,"source":{"system":"sec-edgar","filing":"0001209191-21-013486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013486/doc4.xml","form_type":"4"}},{"id":2839633,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-24T00:44:40.000Z","date":"2021-02-22","kind":"sale","acquired":false,"shares":2891,"price":41.5824,"value":120214.7184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.25 to $42.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2424044,"source":{"system":"sec-edgar","filing":"0001209191-21-013486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013486/doc4.xml","form_type":"4"}},{"id":2839632,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-24T00:44:40.000Z","date":"2021-02-19","kind":"sale","acquired":false,"shares":13233,"price":41.7903,"value":553011.0399,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.34 to $42.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2426935,"source":{"system":"sec-edgar","filing":"0001209191-21-013486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013486/doc4.xml","form_type":"4"}},{"id":2846418,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T13:41:35.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":3710,"price":41.4887,"value":153923.077,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.04 to $41.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2440168,"source":{"system":"sec-edgar","filing":"0000899243-21-007331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007331/doc4.xml","form_type":"4"}},{"id":2846417,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T13:41:35.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":4032,"price":40.4438,"value":163069.4016,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.93 to $40.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2443878,"source":{"system":"sec-edgar","filing":"0000899243-21-007331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007331/doc4.xml","form_type":"4"}},{"id":2846416,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T13:41:35.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":1200,"price":39.4799,"value":47375.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.90 to $39.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2447910,"source":{"system":"sec-edgar","filing":"0000899243-21-007331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007331/doc4.xml","form_type":"4"}},{"id":2850570,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:25:04.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":4060,"price":41.2578,"value":167506.668,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.73 to $41.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2449110,"source":{"system":"sec-edgar","filing":"0000899243-21-007279","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007279/doc4.xml","form_type":"4"}},{"id":2850569,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:25:04.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":1400,"price":40.0019,"value":56002.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.54 to $40.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2453170,"source":{"system":"sec-edgar","filing":"0000899243-21-007279","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007279/doc4.xml","form_type":"4"}},{"id":2850568,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:25:04.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":2000,"price":38.7103,"value":77420.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.21 to $39.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2454570,"source":{"system":"sec-edgar","filing":"0000899243-21-007279","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007279/doc4.xml","form_type":"4"}},{"id":2850567,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:25:04.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":966,"price":42.5273,"value":41081.3718,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.25 to $43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2456570,"source":{"system":"sec-edgar","filing":"0000899243-21-007279","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007279/doc4.xml","form_type":"4"}},{"id":2850566,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:25:04.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":9434,"price":41.7939,"value":394283.6526,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.20 to $42.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2457536,"source":{"system":"sec-edgar","filing":"0000899243-21-007279","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007279/doc4.xml","form_type":"4"}},{"id":2864257,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T22:39:04.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":140000,"derivative":{"exercise_price":3.29,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-21-010312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010312/doc4.xml","form_type":"4"}},{"id":3066025,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-3 Convertible Preferred Stock","published_at":"2020-08-06T10:21:00.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":3631293,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2436773},"source":{"system":"sec-edgar","filing":"0000899243-20-021610","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021610/doc4.xml","form_type":"4"}},{"id":3066024,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-06T10:21:00.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":2436773,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."}],"balance_after":2466970,"source":{"system":"sec-edgar","filing":"0000899243-20-021610","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021610/doc4.xml","form_type":"4"}},{"id":3072593,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T22:38:08.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) July 29, 2021, and (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":22500,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000899243-20-020917","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320020917/doc4.xml","form_type":"4"}},{"id":3214196,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:43:02.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":113400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":113400,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":113400},"source":{"system":"sec-edgar","filing":"0001209191-20-018548","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018548/doc4.xml","form_type":"4"}},{"id":3214195,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:43:02.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":26600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":26600,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":26600},"source":{"system":"sec-edgar","filing":"0001209191-20-018548","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018548/doc4.xml","form_type":"4"}},{"id":3785382,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-10-23T21:10:43.000Z","date":"2018-10-19","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, that were granted in connection with entering into a consulting agreement with the Company to serve as the Company's Chief Development Officer.  One quarter of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal monthly installments over a three year period upon the continued performance of services by the Reporting Person to the Company through the vesting dates.  The option exercise price is the closing price on the date of the grant, October 19, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, that were granted in connection with entering into a consulting agreement with the Company to serve as the Company's Chief Development Officer.  One quarter of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal monthly installments over a three year period upon the continued performance of services by the Reporting Person to the Company through the vesting dates.  The option exercise price is the closing price on the date of the grant, October 19, 2018."}],"balance_after":500000,"derivative":{"exercise_price":9.18,"expiration_date":"2028-10-19","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001144204-18-054993","document":"tv505272_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000114420418054993/tv505272_form4.xml","form_type":"4"}}]}